Clinical Trial Update: A Study of Anlotinib in Subjects With Advanced Malignancy [Phase 2]

View source ↗

Summary

Phase 2 trial update of anlotinib in subjects with advanced malignancy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignancy

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Advanced Malignancy | Phase 2 | Status: COMPLETED